Bolt Biotherapeutics announced its financial results for Q4 and full-year 2025, reporting collaboration revenue of $2.5 million for Q4 and $7.7 million for the year. The company has a cash balance of $31.8 million, expected to fund operations into 2027.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.